To observe the clinical efficacy of Chuanzhi Tongluo Capsules (CZTL) on patients with acute cerebral infarction.Methods:A total of 110 patients with acute cerebral infarction admitted to Zhongshan Hospital Affiliated to Fudan University within 72 hours of onset from January 2018 to December 2019 were divided into an observation group and a control group according to the random number table，with 55 cases in each group.The patients in the control group were treated with conventional western medicine，and those in the observation group received additional CZTL on the basis of the control group.The course of treatment of both groups was 14 days.The NHISS scores，Barthel index，clinical efficacy，adverse reactions during treatment，and changes in serum cytokine levels were observed before treatment and on the 14th day of treatment.Results:On the 14th day of treatment，NIHSS scores decreased and the Barthel index increased in both groups (both P<0.05).The changes in NIHSS score and Barthel index in the observation group were more obvious，but the inter-group difference was not significant (P>0.05).On the 14th day of treatment，the serum levels of TNF-α，IL-1β，and IL-6 in the two groups were significantly reduced (P<0.001)，and the cytokines in the observation group decreased more significantly.The two groups showed a significant difference in IL-6，but no significant difference in TNF-α and IL-1β (P>0.05).No obvious abnormality was observed in IL-8 and IL-10 in the two groups before and after treatment.The total effective rates of the observation group and the control group were 94.55% and 87.27%，respectively.There were no obvious adverse reactions in both groups during the treatment.Conclusion:CZTL can improve neurological function and reduce inflammatory reaction in patients with acute cerebral infarction，with safety and effectiveness.